# Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

> **NCT00096746** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (—)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** LPV/RTV + 2NRTIs
- **DRUG:** LPV/RTV + 2NRTIs

## Key facts

- **NCT ID:** NCT00096746
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 200 (—)
- **Last updated:** 2011-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096746, "Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00096746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*